We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VBI Vaccines Inc | NASDAQ:VBIV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0074 | 1.27% | 0.59 | 0.5703 | 0.5996 | 0.61 | 0.57 | 0.61 | 165,340 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2016
000-13248
(Commission File Number)
VBI VACCINES INC.
(Exact name of Registrant as specified in its charter)
222 Third Street, Suite 2241
Cambridge, Massachusetts 02142
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
On November 9, 2016, VBI Vaccines Inc., a corporation organized under the laws of British Columbia (the “ Company ”), filed on SEDAR at www.sedar.com its (i) unaudited Condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2016 (the “ Q3 Financial Statements ”), (ii) Management’s Discussion and Analysis for the three- and nine-month periods ended September 30, 2016 (the “ Q3 MD&A ”), (iii) Chief Executive Officer Certification of Interim Filings, dated November 9, 2016 (the “ CEO Certification ”) and (iv) Chief Financial Officer Certification of Interim Filings, dated November 9, 2016 (the “ CFO Certification ”). Copies of the Q3 Financial Statements, Q3 MD&A, CEO Certification and CFO Certification are attached hereto as Exhibits 99.1, 99.2, 99.3 and 99.4, respectively, and are incorporated herein by reference.
INCORPORATION BY REFERENCE
Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-212651) and Form S-8 (Registration Number 333-212160) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit Index
Exhibit No. | Description | |
99.1 | Unaudited Condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2016 | |
99.2 | Management’s Discussion and Analysis for the three- and nine-month periods ended September 30, 2016 | |
99.3 | Chief Executive Officer Certification of Interim Filings, dated November 9, 2016 | |
99.4 | Chief Financial Officer Certification of Interim Filings, dated November 9, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VBI Vaccines Inc. | ||
Date: November 9, 2016 | By: | /s/ Jeff Baxter |
Jeff Baxter | ||
President and Chief Executive Officer |
1 Year VBI Vaccines Chart |
1 Month VBI Vaccines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions